Skip to main content

Table 1 Baseline characteristics

From: Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer

 

HLA-A*24:02

HLA-A*24:02

p-value

matched

unmatched

Number of patients

36

27

 

Age, years

62.9 ± 2.1

63.4 ± 2.1

0.7072

Gender

  

0.3074

 Male

17 (47.2%)

17 (63.0%)

 

 Female

19 (52.8%)

10 (37.0%)

 

Stage (UICC)

  

0.7439

 III

7 (19.4%)

5 (18.5%)

 

 IV

26 (72.2%)

21 (77.8%)

 

 Recurrence

3 (8.3%)

1 (3.7%)

 

Tumor marker

   

 CEA

369.2 ± 247.9

8.5 ± 2.1

0.1722

 CA19-9

3870.1 ± 1972.7

3643.2 ± 1444.7

0.0718

  1. Abbreviations: HLA human leukocyte antigen, UICC Union for International Cancer Control, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9